TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Artrya Limited ( (AU:AYA) ) is now available.
Artrya Limited announced the issuance of 200,000 ordinary shares following the exercise of vested performance rights under the company’s incentive plan. This move signifies Artrya’s ongoing efforts to incentivize and reward its stakeholders, potentially impacting its market position and shareholder value.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Artrya Limited is an Australian medical technology company focused on developing AI-powered solutions to enhance the detection and management of coronary artery disease. The company’s proprietary software analyzes coronary CT scans to identify key biomarkers of heart disease, aiding clinicians in more accurate and efficient patient diagnoses. Artrya is committed to advancing cardiac care through innovative technology, with ongoing regulatory and commercial activities in key international markets.
Average Trading Volume: 671,503
Technical Sentiment Signal: Buy
Current Market Cap: A$402.1M
Find detailed analytics on AYA stock on TipRanks’ Stock Analysis page.